Trial Profile
Phase II Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Metastatic or Recurrent Head and Neck Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 May 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Panitumumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms VECTITAX
- 29 Sep 2015 Interim results presented at the European Cancer Congress 2015
- 28 Feb 2015 Status changed from recruiting to completed as reported by European Clinical Trial Database.
- 23 Dec 2010 New trial record